This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Roumen Radinov, Ph.D.
Vice President, Process Sciences at Alnylam Pharmaceuticals


Roumen Radinov received his Ph.D. in organic chemistry from Sofia University, Bulgaria. Following postdoctoral studies in enantioselective methodology and asymmetric synthesis at the University of Geneva, Duke and Stanford, he joined the Roche Chemical Synthesis Department in 1997 where he has developed and scaled up the syntheses of multiple drug candidates including oligonucleotide drug substance and excipients for the Roche siRNA program. In 2012 he joined Alnylam Pharmaceuticals where he is currently Senior Director of drug product development and process development of custom starting materials, excipients, and novel technologies for oligonucleotide manufacture.

Agenda Sessions

  • Adoption of Innovative Technologies in Oligonucleotide Manufacturing: Improving Efficiency of siRNA Manufacturing Processes